SCHEMBL20186946

SCHEMBL20186946

C=CC(=O)Nc1cccc(C)c1Nc1ncnc2c(C(=O)NCCO)csc12

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAPK3 P27361 3/20 0.44
FGFR4 P22455 9/20 0.41
FGFR1 P11362 4/20 0.39
CSF1R P07333 3/20 0.39
RAF1 P04049 2/20 0.39
BRAF P15056 2/20 0.39
DDR1 Q08345 2/20 0.39
DDR2 Q16832 2/20 0.39
ARAF P10398 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
EGFR P00533 1/20 0.39
IRAK4 Q9NWZ3 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20186909 0.86 FGFR4 (0.41) MAPK3FGFR4FGFR1CSF1RRAF1
SCHEMBL20186959 0.86 FGFR4 (0.44) MAPK3FGFR4FGFR1CSF1RRAF1
SCHEMBL20186913 0.84 SRC (0.45) FGFR4FGFR1CSF1RRAF1BRAF
SCHEMBL20186911 0.83 FGFR4 (0.42) FGFR4FGFR1CSF1RRAF1BRAF
SCHEMBL20186929 0.82 FGFR4 (0.54) MAPK3FGFR4FGFR1RAF1BRAF
SCHEMBL20186914 0.82 FGFR4 (0.40) FGFR4FGFR1CSF1RRAF1BRAF
SCHEMBL20186910 0.76 BMX (0.49) FGFR4FGFR1DDR1CYP3A4CYP2D6
SCHEMBL20186950 0.75 BMX (0.61) CSF1RRAF1BRAFDDR1DDR2
SCHEMBL20186916 0.74 MAP3K7 (0.49) FGFR4EGFR
SCHEMBL20186918 0.73 MAPK3 (0.46) MAPK3EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10040803-B2 4-((2-acrylamidophenyl)amino)thieno[3,2-D]pyrimidine-7-carboxamide derivatives as protein kinase inhibitors KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-08-07 US claimed
US-20180148459-A1 4-((2-ACRYLAMIDOPHENYL)AMINO)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-05-31 US claimed
US-10040803-B2 4-((2-acrylamidophenyl)amino)thieno[3,2-D]pyrimidine-7-carboxamide derivatives as protein kinase inhibitors KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-08-07 US disclosed
US-10040803-B2 4-((2-acrylamidophenyl)amino)thieno[3,2-D]pyrimidine-7-carboxamide derivatives as protein kinase inhibitors KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-08-07 US disclosed
US-20180148459-A1 4-((2-ACRYLAMIDOPHENYL)AMINO)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-05-31 US disclosed
US-20180148459-A1 4-((2-ACRYLAMIDOPHENYL)AMINO)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148459-A1 4-((2-ACRYLAMIDOPHENYL)AMINO)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS CDK2, CDK2AP2, CDK2AP1 MAPK3 139/4885FGFR4 1716/4885FGFR1 1214/4885
US-10040803-B2 4-((2-acrylamidophenyl)amino)thieno[3,2-D]pyrimidine-7-carboxamide derivatives as protein kinase inhibitors CDK2, CDK2AP2, CDK2AP1 MAPK3 139/4885FGFR4 1716/4885FGFR1 1214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.